An integrated body composition– immunonutritional signature for predicting immunotherapy response and prognosis in gastric cancer: a multicenter retrospective cohort study - Top-Institutions - MDSpire

An integrated body composition– immunonutritional signature for predicting immunotherapy response and prognosis in gastric cancer: a multicenter retrospective cohort study

  • By

  • Fang Li

  • Tao Zheng

  • Honghai Guo

  • Peigang Yang

  • Ning Meng

  • Xiaolong Li

  • Zhenjiang Guo

  • Yuan Tian

  • Qun Zhao

  • July 15, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Fourth Hospital of Hebei Medical University
    Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei

    Key Differentiators

    • Oncology

  • #2

    Shijiazhuang People’s Hospital
    Shijiazhuang People’s Hospital

    Shijiazhuang, Hebei

    Key Differentiators

    • Oncology

  • #3

    Baoding Central Hospital
    Baoding Central Hospital

    Baoding, Hebei

    Key Differentiators

    • Oncology

  • #4

    Hengshui People’s Hospital
    Hengshui People’s Hospital

    Hengshui, Hebei

    Key Differentiators

    • Oncology

  • #5

    Peking University Cancer Hospital
    Peking University Cancer Hospital

    Beijing, Beijing

    Key Differentiators

    • Oncology

Original Source(s)

An integrated body composition– immunonutritional signature for predicting immunotherapy response and prognosis in gastric cancer: a multicenter retrospective cohort study

  • by Fang Li, Tao Zheng, Honghai Guo, Peigang Yang, Ning Meng, Xiaolong Li, Zhenjiang Guo, Yuan Tian, Qun Zhao

  • July 15, 2026

Related Content

From associations to clinical practice: translating inflammatory-nutritional indices into a machine learning-driven model for breast cancer risk stratification with cross-ethnic validation

Prediction models for postoperative recurrence in papillary thyroid carcinoma: a systematic review and critical appraisal

Treatment patterns and outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia: a single center study from Oman